Completed PHASE3 INTERVENTIONAL NCT00079989

Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms

A Phase 3, Open-label, Noncomparative Study of Tigecycline for the Treatment of Subjects With Selected Serious Infections Due to Resistant Gram-negative Organisms Such as Enterobacter Species, Acinetobacter Baumannii, and Klebsiella Pneumoniae

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Conditions Gram-Negative Bacterial Infections

Interventions tigecycline

Updated 6 times since 2017 Last updated: Feb 7, 2013 Started: Dec 31, 2003 Primary completion: Nov 30, 2005 Completion: Nov 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Gram-Negative Bacterial Infections and is currently completed. Wyeth is now a wholly owned subsidiary of Pfizer leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Wyeth is now a wholly owned subsidiary of Pfizer

Data source: Wyeth is now a wholly owned subsidiary of Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.